Discounted Cash Flow (DCF) Analysis Unlevered

Leap Therapeutics, Inc. (LPTX)

$1.17

-0.04 (-3.31%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 1.17 | undervalue

Operating Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 1.17
Beta 0.564
Diluted Shares Outstanding 85.83
Cost of Debt
Tax Rate 0.06
After-tax Cost of Debt -9.48%
Risk-Free Rate
Market Risk Premium
Cost of Equity 5.448
Total Debt 0.43
Total Equity 100.42
Total Capital 100.85
Debt Weighting 0.43
Equity Weighting 99.57
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 0.53%-0.09%0.01%0.01%0.06%0.10%0.10%0.10%0.10%0.10%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -0.06--0.100.03------
UFCF ----------
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 5.38
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -114.48
Equity Value -
Shares Outstanding 85.83
Equity Value Per Share -